Cargando…
Multiple sclerosis patients and COVID-19
Coronavirus disease 2019 (COVID-19) is now a major issue for all fields of medicine. Due to the higher mortality rate among patients with chronic diseases, it has also caused concern in patients with multiple sclerosis (MS), who in addition are often receiving immunosuppressive drugs. The aim of thi...
Autores principales: | Mado, Hubert, Adamczyk-Sowa, Monika |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985914/ https://www.ncbi.nlm.nih.gov/pubmed/33776407 http://dx.doi.org/10.1186/s41983-021-00287-3 |
Ejemplares similares
-
Comment on the paper Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab: the likely explanation for this phenomenon based on our observations
por: Mado, Hubert, et al.
Publicado: (2021) -
SARS-CoV-2/COVID-19 in multiple sclerosis patients receiving disease-modifying therapy
por: Adamczyk-Sowa, Monika, et al.
Publicado: (2021) -
Anti-severe acute respiratory syndrome coronavirus-2 antibody responses following Pfizer-BioNTech vaccination in a patient with multiple sclerosis treated with ocrelizumab: a case report
por: Mado, Hubert, et al.
Publicado: (2021) -
Role of Microglial Cells in the Pathophysiology of MS: Synergistic or Antagonistic?
por: Mado, Hubert, et al.
Publicado: (2023) -
The influence of sodium on pathophysiology of multiple sclerosis
por: Zostawa, Jacek, et al.
Publicado: (2017)